Rouet François, Ekouevi Didier K, Inwoley André, Chaix Marie-Laure, Burgard Marianne, Bequet Laurence, Viho Ida, Leroy Valériane, Simon François, Dabis François, Rouzioux Christine
Centre de Diagnostic et de Recherches sur le SIDA, CHU de Treichville, BP V3 Abidjan, Côte d'Ivoire.
J Clin Microbiol. 2004 Sep;42(9):4147-53. doi: 10.1128/JCM.42.9.4147-4153.2004.
We evaluated a two-rapid-test serial algorithm using the Determine and Genie II rapid assays, performed on-site in four peripheral laboratories during the French Agence Nationale de Recherches sur le SIDA (ANRS) 1201/1202 Ditrame Plus cohort developed for prevention of mother-to-child transmission of human immunodeficiency virus (HIV) infection in Côte d'Ivoire. A total of 1,039 specimens were retested by two commercial enzyme-linked immunosorbent assays (ELISAs). The following specimens were tested: 315 specimens found on-site to be infected with HIV type 1 (HIV-1), 8 specimens found on-site to be infected with HIV-2, 71 specimens found on-site to be infected with both HIV-1 and HIV-2, 40 specimens found on-site to have indeterminate results for HIV infection, and 605 specimens taken during a quality assurance program. For HIV discrimination, 99 positive serum samples (20 with HIV-1, 8 with HIV-2, and 71 with HIV-1 and HIV-2 on the basis of our rapid test algorithm) were retested by the Peptilav test, Western blot (WB) assays, and homemade monospecific ELISAs. Real-time DNA PCRs for the detection of HIV-1 and HIV-2 were performed with peripheral blood mononuclear cells from 35 women diagnosed on-site with HIV-1 and HIV-2 infections. Compared to the results of the ELISAs, the sensitivities of the Determine and Genie II assays were 100% (95% lower limit [95% LL], 99.1%) and 99.5% (95% confidence interval [95% CI], 98.2 to 99.9%), respectively. The specificities were 98.4% (95% CI, 96.9 to 99.3%) and 100% (95% LL, 99.3%), respectively. All serological assays gave concordant results for infections with single types. By contrast, for samples found to be infected with dual HIV types by the Genie II assay, dual reactivity was detected for only 37 samples (52.1%) by WB assays, 34 samples (47.9%) by the Peptilav assay, and 23 samples (32.4%) by the monospecific ELISAs. For specimens with dual reactivity by the Genie II assay, the rates of concordance between the real-time PCR assays and the serological assays were 25.7% for the Genie II assay, 82.9% for the Peptilav assay, 74.3% for WB assays, and 80% for the homemade ELISAs. Our algorithm provided high degrees of sensitivity and specificity comparable to those of ELISAs. Even if they are rare, women identified by the Genie II assay as being infected with HIV-1 and HIV-2 mostly appeared to be infected only with HIV-2.
我们评估了一种使用Determine和Genie II快速检测法的两步快速检测连续算法,该算法在法国国家艾滋病研究机构(ANRS)1201/1202 Ditrame Plus队列研究中,于科特迪瓦的四个外围实验室现场进行,该队列研究旨在预防人类免疫缺陷病毒(HIV)感染的母婴传播。总共1039份标本通过两种商业酶联免疫吸附测定(ELISA)进行了重新检测。检测了以下标本:现场发现315份标本感染1型HIV(HIV-1),8份标本感染2型HIV(HIV-2),71份标本同时感染HIV-1和HIV-2,40份标本HIV感染结果不确定,以及605份在质量保证计划期间采集的标本。为了进行HIV鉴别,对99份阳性血清样本(根据我们的快速检测算法,20份感染HIV-1,8份感染HIV-2,71份同时感染HIV-1和HIV-2)进行了Peptilav检测、免疫印迹(WB)测定和自制单特异性ELISA检测。对35名现场诊断为感染HIV-1和HIV-2的女性的外周血单个核细胞进行了用于检测HIV-1和HIV-2的实时DNA PCR检测。与ELISA结果相比,Determine和Genie II检测的灵敏度分别为100%(95%下限[95% LL],99.1%)和99.5%(95%置信区间[95% CI],98.2至99.9%)。特异性分别为98.4%(95% CI,96.9至99.3%)和100%(95% LL,99.3%)。所有血清学检测对单一类型感染的结果一致。相比之下,对于Genie II检测发现感染两种HIV类型的样本,WB检测仅检测到37份样本(52.1%)有双重反应性,Peptilav检测检测到34份样本(47.9%)有双重反应性,单特异性ELISA检测检测到23份样本(32.4%)有双重反应性。对于Genie II检测有双重反应性的标本,实时PCR检测与血清学检测之间的一致性率,Genie II检测为25.7%,Peptilav检测为82.9%,WB检测为74.3%,自制ELISA检测为80%。我们的算法提供了与ELISA相当的高灵敏度和特异性。即使很少见,Genie II检测鉴定为感染HIV-1和HIV-2的女性大多似乎仅感染了HIV-2。